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Abstract. The modern era of targeted therapeutics offers
the potential to tailor therapy to individual patients whose
tumours express a specific target. Previous attempts to
forecast tumour response to conventional chemotherapeutics
based on similar principles have however been disappointing.
Mitomycin C (MMC), for example, is a bioreductive drug
that requires metabolic activation by cellular reductases for
activity. The enzyme NAD(P)H:Quinone oxidoreductase-1
(NQO1) can reduce MMC to DNA damaging species but
attempts to establish the relationship between tumour
response to MMC and NQO1 expression have generated
conflicting reports of good and poor correlations. Several
other reductases are known to activate MMC. This, in
conjunction with the fact that various physiological and
biochemical factors influence therapeutic response, suggests
that the mechanism of action of MMC is too complex to
allow tumour response to be predicted on the basis of a
single enzyme. Alternative approaches using more complex
biological and pharmacological systems that reflect the
spectrum of reductases present within the tumour have been
developed and it remains to be seen whether or not the
predictive value of these approaches is enhanced. With
regards to targeted therapeutics, the experience with MMC
suggests that prediction of tumour response based on
analysis of a single target may be too simplistic. Multiple
mechanisms of action and the influence of tumour
microenvironment on cell biology and drug delivery are likely
to influence the final outcome of therapy. The challenge for
the future progression of this field is to develop assays that
reflect the overall biological and pharmacological processes
involved in drug activation whilst retaining the simplicity and
robustness required for routine chemosensitivity testing in a
clinical setting. 
The ability to tailor chemotherapy to individual patients who
are most likely to benefit from treatment has been a major
objective in cancer research for many years. Since the seminal
studies of Hamburger and Salmon in the late 1970’s where
primary cell cultures and clonogenic assays were used (1),
numerous approaches have been evaluated. Despite extensive
research, the ability to accurately forecast the response of
individual patients to chemotherapy remains elusive. The
modern era of targeted therapeutics offers enhanced
prospects of individualised therapy. The development of
trastuzumab for use against HER-2 positive breast cancers is
a good example of this (2, 3). Whilst the example of
trastuzumab represents a significant step forward
individualised therapy, is it realistic to expect that all tumours
that express a specific target will respond to target orientated
therapies? Even in the case of trastuzumab, tumour response
remains heterogeneous with some patients responding well
whereas others are inherently resistant to treatment (4).
Numerous attempts have been made to predict the response
of tumours to conventional cytotoxics using similar
approaches. However, no reliable assay is currently in routine
clinical use. In this article, the predictive value of assays
designed to forecast the response of tumours to mitomycin C
(MMC, Figure 1) will be critically reviewed. The rationale for
selecting MMC is that it is a targeted anticancer agent and
extensive efforts have been made to predict tumour response
based upon analysis of key enzymes involved in its
mechanism of action. The principle objective of this review is
to obtain an understanding of why previous approaches have
been unsuccessful in the belief that this may inform the
design of predictive assays for targeted therapeutics. 
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MMC and the Potential for Tailored Therapy
MMC is a naturally occurring antibiotic that was isolated
from Streptomyces caespitosis in 1956 by Hata et al. (5). It
belongs to a class of anticancer agents known as
bioreductive drugs and it is regarded as the prototypical
bioreductive drug (6). MMC is a clinical component of
combination chemotherapy regimens used to treat a range
of tumour types (7). Throughout Europe, MMC is routinely
used as a single agent to treat superficial bladder cancers
and it significantly delays tumour recurrence (8, 9). The
response of superficial bladder cancers to MMC is
heterogeneous (10). So there is a clinical need to identify
patients that are most likely to benefit from treatment. 
In general terms, bioreductive drugs are molecules that
require metabolic activation by cellular reductases to
generate metabolites that damage DNA. They were initially
developed to target hypoxic cells and selectivity was
determined by the ability of oxygen to reverse the activation
process (11, 12). As our understanding of the enzymatic
activation processes increased, it became clear that certain
bioreductive drugs can also target aerobic cells (13). In this
case, selectivity is determined primarily by the presence of
elevated levels of reductase activity in tumour tissue (13).
This generated the concept of ‘enzyme directed bioreductive
drug development’, an integral component of which is the
ability to forecast tumour response based upon knowledge
of the activity of specific reductases and/or the extent of
tumour hypoxia (14). Whilst conceptually elegant, its
ultimate value depends upon a number of conditions. The
main requirement is that one enzyme plays a dominant role
in bioreductive activation and that tumour response is
determined by the expression of this enzyme in tumours.
Furthermore, it also assumes that cells ability to respond to
DNA damage (DNA repair or ability to undergo apoptosis)
play a comparatively minor role in determining response.
The ability to predict tumour response based upon analysis
of a single enzyme and approaches that challenge the
assumptions outlined above will, therefore, be the initial
focus of this review. 
MMC and its Mechanism of Action
The mechanism of action of MMC has been extensively
studied and reviewed elsewhere (15-18). Briefly, the initial
and critical step in the bioactivation process is reduction of
the quinone to either the semiquinone or the hydroquinone
by one- or two-electron reductases, respectively (Figure 1).
In the presence of oxygen, the semiquinone enters into a
redox cycle that produces reactive oxygen species (ROS)
which can lead to DNA damage. It is generally
acknowledged, however, that the DNA damage caused by
ROS contributes little to the overall cytotoxicity of MMC
compared to DNA alkylation (19, 20). Under hypoxic
conditions, the semiquinone free radical chemically
rearranges into the more stable hydroquinone which
undergoes a series of chemical reactions leading ultimately
to alkylation of DNA (21). When the hydroquinone species
are generated directly by 2 electron reductases (by passing
the semi-quinone), the generation of alkylating species is
not dependent upon the presence or absence of oxygen. The
covalent DNA adducts produced are predominantly formed
at the N2 position of guanine (but also at the N7 position)
and both intra-strand and inter-strand crosslinks as well as
mono-adducts are produced. It is however the interstrand
cross links rather than the monoadducts that are critical
factors in determining cell death (22). 
Physiological conditions, such as low pH (23, 24) and
oxygen tension (25, 26) can have a significant influence on
cellular response to MMC but the key step in the process
remains the initial reduction of the quinone nucleus by one
and/or two electron reductases. Numerous enzymes have
been implicated in the reduction of MMC. These include
cytochrome P450 reductase (27), xanthine dehydrogenase
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Figure 1. Basic schematic of MMC bioactivation. For a more complete
overview of the full metabolic route, see Cummings et al. (17).
(28), xanthine oxidase (29, 30), NADPH ferredoxin
reductase (31), cytochrome b5 reductase (32), an
uncharacterised cytosolic enzyme (15, 33), glucose
regulatory protein 58 (34, 35), HAP1 (35), NQO1 (36) and
more recently NAD(P)H:Quinone oxidoreductase 2 (37,
38). Whilst MMC is a substrate for many enzymes, attention
has predominantly focused on NQO1 (17, 18, 39) and the
relationship between NQO1 and response to MMC has
been extensively studied. In addition to enzymatic
reduction, a series of other events should be taken into
consideration as these may also determine cellular response.
These are summarised in simplified form in Figure 2 and
include; reduction of MMC by reductases and other
metabolic routes such as detoxification pathways, the
formation of DNA damage and its repair, and finally the
induction of cell death. Similar reasoning could be extended
to other forms of targeted therapy in terms of the presence
of an active target, the target/drug interaction, the effect of
this interaction (e.g. activation or repression of a signalling
pathway, tubulin disruption) and the induction of cell death.
Each step of this process may be of importance in predicting
response to treatment and will be commented upon in this
review. Initially however, the relationship between NQO1
and response to MMC will be discussed.
Role of NQO1 in MMC Bioactivation and
the Prospect of Individualising Therapy 
Based on NQO1 Expression
NQO1 is a cytosolic flavoprotein that catalyses the two-
electron reduction of a broad range of substrates
(particularly quinone based compounds) using NADH or
NADPH as the source of electrons (18, 40, 41). Several
possible physiological functions for NQO1 have been
proposed (42, 43) although historically, its role in protecting
cells from highly reactive environmental and synthetic
quinones is believed to be its principle function. This is
achieved by converting quinones directly into redox stable
hydroquinones, thereby bypassing the semi-quinone free
radical and subsequent generation of ROS caused by redox
cycling in air. The newly formed hydroquinones can be
conjugated to glucoronides or sulfides, resulting in increased
water solubility and excretion (44). In the case of certain
quinones however, the hydroquinone may itself autoxidise to
generate ROS or directly alkylate DNA. In these cases,
reduction by NQO1 represents a pro-drug activation
mechanism. The decision as to whether a compound is
detoxified or activated by NQO1 is determined largely by the
chemistry of the groups attached to the quinone nucleus
(44). In the case of MMC, it is a substrate for NQO1 and
reduction by NQO1 results in DNA alkylation in cell free
assays (36, 45, 46). This fact alone suggests that NQO1 could
play a significant role in determining therapeutic response. 
Two additional pieces of evidence significantly enhanced
the prospect of predicting response to MMC based on
analysis of NQO1. First, a series of studies demonstrated
that the expression of NQO1 (at the mRNA and protein
level) was not only elevated in several tumour types but that
within each pathological group of tumours, wide
interpatient heterogeneity existed (47-49). Some patient’s
tumours expressed high levels of NQO1 activity whereas
others were devoid of activity, making it was conceivable
that heterogeneity in tumour response to MMC could be
related to heterogenous NQO1 expression. Second, the
gene encoding for NQO1 is polymorphic and two single
nucleotide polymorphic (SNP) variants (C609T [NQO1*2]
and C465T [NQO1*3]) are associated with total loss or
significant reductions in NQO1 activity (50-53). In view of
the fact that NQO1 can activate MMC, wide variations in
NQO1 activity or the presence of SNP’s leading to reduced
NQO1 activity could have a significant bearing on
therapeutic outcome (41). It should be stressed however
that the ability of NQO1 to reduce MMC is not simple as it
only occurs under mild acidic conditions (45). At
physiological pH values, MMC is not only a poor substrate
for NQO1 but actually inhibits NQO1 activity (23, 45, 54).
Whilst tumours are known to contain regions of low
extracellular pH 55, intracellular pH is generally maintained
at or slightly above neutrality (56). These findings may
impact on the relevance of NQO1 as a major determinant
of MMC activity as discussed below. 
Relationship between NQO1 and Response 
to MMC In Vitro
As stated previously, the existence of a correlation between
reductase expression (mRNA and/or protein) and treatment
response is an essential requirement for enzyme directed
drug development. Several experimental approaches have
been employed but as described below, conflicting reports
of good and poor correlations between NQO1 expression
and response in vitro can be found within the available
literature. In studies using panels of cell lines that inherently
express a broad range of NQO1 mRNA and/or protein,
reports of good correlations between NQO1 activity and
response (57-61) contrast sharply with reports of poor
correlations (15, 62-64). Similarly, enhanced activity of
MMC has been observed by some groups in isogenic cell
lines where NQO1 has been over expressed (65-68) whereas
other laboratories have demonstrated that MMC sensitivity
is independent of NQO1 activity in similar models (15, 69,
70). Several studies using cell lines that are resistant to
MMC have demonstrated that NQO1 activity is reduced
compared to the parental lines (58, 71). Other studies have
demonstrated that cisplatin resistant A2780 cells (which
have elevated levels of NQO1) are also resistant to MMC,
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which suggests that other factors influence the outcome of
MMC treatment (72). Attempts to chemically modulate
NQO1 activity in cell lines, using the inhibitor dicumarol for
example, have suggested that NQO1 plays a role in
activating MMC (73, 74). Similarly, NQO1 activity can be
induced in cells and enhanced toxicity to MMC has been
observed following NQO1 induction by 1,2-dithiole-3-
thione, dimethyl fumarate and arsenite (75-77). However,
caution needs to be exercised in the interpretation of these
experiments as dicumarol is not a selective inhibitor of
NQO1 (78) and the recent finding that NQO1 can stabilise
p53 (79, 80) suggest that manipulation of NQO1 levels in
cells could potentially modulate therapeutic response to
DNA damage.
The majority of the studies mentioned above have
focused on the relationship between NQO1 and response
to MMC under aerobic conditions but the situation
becomes more complex when similar experiments are
conducted under hypoxic conditions. The determination of
hypoxic cytotoxicity ratios (HCR; defined as the ratio of
IC50 values in air divided by IC50 values under hypoxia) is
a commonly used method to compare the activity of drugs
under both aerobic and hypoxic conditions. In the case of
MMC, high HCR values have been reported in cell lines
that have low or no NQO1 activity (26, 81). In NQO1 rich
cells, HCR values are typically very low, indicating that
these cells are equally sensitive to MMC in the presence
and absence of oxygen (26, 82). Whilst the mechanistic
basis for these observations is not fully understood, these
results present a significant additional challenge to
predictive drug testing for MMC sensitivity based on the
analysis of NQO1 alone.
With regards to the potential impact of NQO1 SNP’s on
MMC sensitivity, resistance to MMC has been
demonstrated in a number of cell lines that are homozygous
for the NQO1*2 allele (53, 83). Similarly for the NQO1*3
allele, cells are more resistant to MMC than wild-type cells
(84, 85). Furthermore, the response of primary cell lines
derived from gastric tumours to MMC was dependent upon
NQO1 genotype, with increased sensitivity to MMC
observed in cells with wild-type NQO1 (86). In contrast to
studies based on NQO1 phenotypic expression or activity,
no studies have been published that contradict these
findings and experimentally at least, genotype status
provides the strongest evidence that NQO1 plays a role in
determining therapeutic outcome to MMC treatment. 
Relationship between NQO1 and Response to
MMC in Xenografts and Patients
The ability to predict response to MMC based upon analysis
of NQO1 phenotype and genotype has been critically
addressed in a series of in vivo and clinical studies. With
regards to NQO1 phenotype, a good correlation between
MMC sensitivity in vivo and NQO1 activity was reported in
a panel of eight non-small cell and small cell lung tumour
xenografts (48). In other studies, however, a poor correlation
between anti-tumour activity and NQO1 levels has been
reported (87-89). In an extensive panel of 45 human tumour
xenografts expressing a broad spectrum of NQO1 enzyme
activity, no correlation was observed between NQO1 activity
and response to MMC in vivo (64). In clinical studies,
promising results were obtained by Gan et al. where the
response of histocultures derived from 21 human bladder
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Figure 2. Simplified cartoon outlining the key steps required for cellular response to MMC. 1; presence of reductases/target protein, 2; MMC metabolism
or drug/target interaction, 3; DNA damage or effect of target disruption, 4; Cell death induction.
cancer patients (with both superficial and invasive disease)
correlated with the mRNA expression of NQO1 and
cytochrome P450 reductase (90). In contrast, NQO1 protein
expression as measured by immunohistochemistry in 92
superficial bladder cancers (pathology was restricted to
G1/G2 and pTa/T1 tumours) did not correlate with clinical
response to MMC in terms of time to first recurrence (91). 
With regards to the polymorphic variants of NQO1, a study
by Fleming et al. reported that in 117 patients with
disseminated peritoneal cancer treated with intraperitoneal
hyperthermic MMC, patients that were heterozygous or
homozygous with respect to NQO1*2 had reduced survival
compared to patients genotyped as wild-type (92). This very
significant finding suggested for the first time that screening
for this polymorphism may be useful in identifying individuals
who may be at risk of treatment failure following
intraperitoneal MMC therapy. In contrast to these
encouraging reports, studies in both human tumour xenografts
(93) and superficial bladder cancer patients (94) have
demonstrated that genotyping individuals with respect to the
NQO1*2 SNP did not correlate with therapeutic outcome. 
In summary, the ability to forecast the response of
tumours based on the levels of NQO1 or NQO1 genotype
status is unlikely to be of practical value in the clinic. Whilst
some evidence of positive correlations have been reported,
there is a wealth of conflicting data in the literature which
suggests otherwise. A number of other enzymes have been
implicated in the activation of MMC and some attempts
have been made to correlate their expression status,
sometimes in conjunction with the NQO1 levels, with
response to MMC treatment. It remains to be seen whether
the response of tumours to MMC can be forecast based on
the expression of these enzymes but, the complexity of
MMC activation suggests that this approach is unlikely to
be productive. Models or assays that mimic more closely the
complexity of the biological system offer a potential way
forward and some of these approaches are discussed in the
following sections. 
Analysis of MMC Metabolism in Crude Tumour
Homogenates; Relationship with Cellular and
Tumour Response to MMC
As multiple enzymes are involved in the activation of MMC,
Cummings et al. proposed an alternative approach based
upon the ability of tumour homogenates to metabolically
activate MMC (17). This represented the first move from
single enzyme/marker prediction to multiple enzyme activity
assessment and it is based on the rationale that tumour
homogenates will contain a ‘cocktail’ of reductases capable
of activating MMC. By using analytical techniques
identifying active metabolites, a more accurate assessment
of a tumour’s ability to activate MMC may therefore be
achieved (17). Initial studies focused on the identification
of 2,7-diaminomitosene (2,7-DAM) as an indicator of
bioreductive activation. 2,7-DAM is a transient intermediate
formed after the reduction of MMC and it is used as a
marker of drug activation (Figure 1). In two murine colon
carcinoma models (MAC 16 and MAC 26) 2,7-DAM was
readily detected in tumours following intra-tumoral
injection of MMC (15). However, higher levels of 2,7-DAM
were detected in the comparatively more resistant MAC 26
tumour model compared to MAC 16 tumours, indicating
that other pharmacological factors have a significant
influence of therapeutic outcome. The analysis of 2,7-DAM
is however technically challenging as it is a reactive
metabolite that readily binds covalently to cellular
macromolecules and once bound, it will be invisible to the
majority of analytical techniques.
In an attempt to circumvent this issue, studies conducted
in our laboratory analysed the ability of tumour
homogenates from a panel of resistant and sensitive human
tumour xenografts to metabolise MMC (64). The rate of
metabolism of the parent MMC compound was significantly
greater in the MMC sensitive group (tó=75±48.3 min,
n=6) compared to the resistant group (tó=280±129.6 min,
n=11). Based upon these results, a pilot study was
established in 30 patients with superficial (G1/G2 and
pTa/T1) bladder cancer where surgical specimens were
immediately flash frozen in liquid nitrogen and transferred
to the laboratory. Using identical methodologies to our
previous studies (64), this study demonstrated that the
ability of tumour homogenates to metabolise MMC varied
considerably between individual tumours with half lives
ranging from 17.5 min to >1000 min (Figure 3). 
The key question was whether or not these inherent
differences in the ability of tumours to metabolise MMC
translates into differences in therapeutic response.
Following tumour resection, each patient received a single
dose of MMC (40 mg/40 ml) administered intravesically
within 24 hours of surgery and time to first recurrence was
determined by established follow up procedures. No trend
could be established between either metabolism rates and
time to first recurrence or metabolism rates and the
presence or absence of recurrent disease at the time of
survey. Surprisingly, some tumours that slowly
metabolised MMC in vitro responded as well to MMC as
tumours that rapidly metabolised MMC (patients A and
B, Table I). Within the G2/pTa tumours, 3 patients
suffered recurrence following MMC therapy. Patients C
and D, had similar clinical response (first recurrence 3
months after MMC therapy) despite the fact that tumour
homogenate from patient C metabolised MMC rapidly
(t1/2=17.5 min) whereas tumour homogenate from patient
D metabolised MMC more slowly (t1/2=395 min) (Table
I). The observation that several of the tumours that
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metabolised MMC slowly responded well to treatment
(Table I) implies that only a small fraction of MMC is
needed to be activated to DNA damaging species or that
the tumour cells themselves are exquisitely sensitive to
low levels of DNA damage. On the other hand, several
tumours were able to metabolise MMC rapidly but failed
to respond well to treatment (Table I). This suggests that
metabolism of MMC is not only a reflection of
bioreductive activation but also of other metabolic routes
such as detoxification pathways. 
The glutathione-glutathione S transferase pathway is a
known resistance mechanism for MMC (95). To exemplify
this, additional studies in our laboratory have analysed the
effect of glutathione depletion by the non-toxic agent L-
buthionine-R,S-sulfoximine (BSO) on in vitro
chemosensitivity to MMC. The IC50 obtained after
treatment of H460 cells with BSO for 24 hours (50 ÌM)
followed by exposure to a range of MMC concentrations for
1 hour, were 1.45±0.91 ÌM, compared to 0.77±0.28 ÌM in
the absence of BSO (Figure 4). In contrast, exposure of
RT4 cells to BSO prior to MMC treatment induced a 6.5-
fold decrease in the IC50, from 30.20±7.33 ÌM down to
4.62±3.80 ÌM (Figure 4). These results suggested that
inherent differences in detoxification pathways (e.g.
glutathione) existed between RT4 and H460 cells that could
have had a significant bearing on MMC sensitivity. 
In summary, whilst significant differences exist in the
ability of tumours to metabolise MMC, the lack of
correlation between metabolic rates and tumour response
suggests that this approach needs to be refined. The ability
to measure active metabolites, the role of detoxification
pathways and the destruction of tumour microenvironments
during the preparation of homogenates represent significant
obstacles that would have to be addressed. 
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Figure 3. Relationship between MMC metabolism by bladder tumour
homogenates and clinical response to MMC. Protein homogenates (10
mg/ml) were then incubated at 37ÆC in the presence of 2 mM NADH and
2 mM NADPH and the reaction was initiated by the addition of MMC
(200 ÌM). At various time intervals, 30 Ìl of the reaction mixture was
removed and added to 90 Ìl of acetonitrile containing the internal
standard, porfiromycin (PFC, 50 ÌM). Samples were evaporated and
resuspended in mobile phase. Chromatographic separation of MMC by
HPLC has been described previously (64). Detection of MMC is
performed at 365 nm and 310 nm with a flow rate of 1 ml/min. The half-
life of MMC was determined from least squares log linear regression
analysis t1/2=0.693/Kd where Kd is the decay rate constant (the slope of
the regression analysis x 2.303).
Figure 4. The influence of the glutathione detoxification pathway on
MMC cytotoxicity in human cancer cell lines. The effect of the glutathione
detoxification pathway was evaluated, using BSO, an inhibitor of
glutathione synthesis, reported to be effective when used at 50 ÌM for 24
h (118). Cells were plated into 96 well culture plates incubated overnight.
The following day, cells were incubated with BSO (50 ÌM) or fresh
medium for 24 h. Cells were then exposed to a range of MMC
concentrations (0.2 ÌM to 100 ÌM) for 1 h in absence of BSO, after which
they were washed twice with HBSS prior to addition of complete media.
Cell survival was assessed using the MTT assay. IC50 values are expressed
in terms of the mean±standard deviation for three independent
experiments. MMC cytotoxicity in H460 and RT4 cells pre-treated with 50
ÌM BSO (●) for 24 h or in absence of BSO (●). Each data point
represents the mean±SD for 3 independent experiments.
Table I. MMC half-life and clinical response obtained for 4 superficial
bladder cancer patients treated with MMC. These patients were selected
to illustrate the extremes of both clinical response to MMC and MMC
metabolic rates.
Patients Tumour MMC half-life Time to first recurrence 
grade (min) (month)
A G1/pTa 93 >27
B G1/pTa 853 >24
C G2/pTa 17 3
D G2/pTa 395 3
Induction and Response to DNA Damage 
as an Indicator of MMC Sensitivity
Developing the approach outlined by Cummings et al. (17),
analysis of DNA damage induction in tumour cells would
represent not only the end product of bioreductive
activation by multiple enzymes but would also take into
account the role played by detoxification pathways and
other protein/drug interaction. Analysis of DNA damage
induction may therefore provide an indication of
bioreductive activation. As mentioned previously and
discussed in detail elsewhere (16, 17, 22), MMC induces a
range of DNA lesions but inter-strand cross links are
regarded as the major cytotoxic lesions (22). In a panel of
human tumour cell lines, in vitro chemosensitivity to MMC
correlated well with the induction of DNA inter-strand
crosslinks as measured by the comet assay (96). This study
demonstrated that analysis of DNA interstrand crosslink
formation provides a good indicator of MMC
chemosensitivity in vitro and further studies are required to
assess the relationship between DNA interstrand cross link
formation and response to MMC in vivo (96). 
Two other factors need to be taken into consideration in
view of these findings; the ability of cells to repair DNA
damage and the response of cells to DNA damage in terms
of their ability to undergo apoptosis. With regards to DNA
repair, full details of the mechanism of DNA repair of
MMC induced DNA damage remains unclear but it involves
multiple repair pathways including nucleotide excision
repair, homologous recombination repair and translesion
bypass repair pathways (97, 98). In contrast to the
relationship between interstrand crosslink formation and
response, poor correlations between response and DNA
repair kinetics (determined by the comet assay) and
apoptosis induction (determined by Annexin V-FITC/PI
dual staining and Hoescht 33342 staining) were observed
(96). Whilst DNA repair processes can generally influence
therapeutic response, the data presented in this study
suggests that it plays a minor role in determining response
to MMC. These findings were in agreement with similar
studies analysing the role played by DNA repair in
determining response to radiotherapy were no correlation
could be established between the two parameters in vitro
(99-101) and in patients with acute myeloid leukaemia
(102). In terms of apoptosis induction, conflicting reports of
the relevance of apoptosis to MMC sensitivity have been
published. Some studies showed a trend between response
to MMC and the levels of apoptosis measured in cell lines
and in bladder tumours exposed the drug ex vivo (103, 104),
whereas other reports showed a lack of correlation between
the two parameters (105-108). The latter were in accordance
with a review by Okada and Mak describing how DNA
damage could trigger processes of senescence or mitotic
catastrophe rather than programmed cell death (109).
However, a recent study which used 20 non small cell lung
carcinoma samples suggested the existence of a relationship
between the levels of apoptosis induced by ex vivo exposure
to MMC, cisplatin and taxotere and reduced metabolic
activity in the cultured samples (110). They highlighted the
usefulness of measuring pharmacodynamic parameters of
tumour mass cultured and treated ex vivo in order to predict
response (110).
The correlation observed between inter-strand crosslink
formation and response suggested that the process of
bioreductive activation remains the major determinant of
cellular response to MMC at least in vitro and further
studies are required to determine whether or not the comet
assay can accurately forecast the response of tumours to
MMC in vivo. The comet assay encompasses the key
principles developed above in that it is a cell based assay
where bioreductive activation processes take place alongside
detoxification pathways in a competitive manner. Recent
studies have also demonstrated that the comet assay
provides a good indication of response to radiotherapy, is
simple, inexpensive, rapid and requires small biopsy samples
(99-101, 111). It remains to be seen whether or not the
comet assay can be used to accurately forecast the response
of superficial bladder cancers to MMC. 
Conclusion
Two main issues arise from this review. The first relates to
the prospects for developing predictive assays for MMC and
the second is what lessons can be drawn from MMC that
can or should be considered when developing predictive
assays for targeted therapies. 
With regards to MMC specifically, there is sufficient
uncertainty and conflict in the literature to indicate that
analysis of NQO1 alone is unlikely to be beneficial in terms
of predicting response. Whether correlations can be
obtained between the expression of other reductases
involved in MMC activation and response remains to be seen
but the complexity of MMC’s mechanism of action would
suggest that this approach is unlikely to be productive. Cell
based assays are a promising way forward as they retain a
degree of complexity within the system but this may be
compromised by the fact that disruption of solid tumours
would also destroy local tumour microenvironments that can
influence the activity of MMC. Exposure of biopsies to
MMC prior to disaggregating the tissue may circumvent this
although this introduces additional problems concerning
drug delivery and changes in microenvironmental conditions
during drug exposure. Significant obstacles therefore exist in
relation to solid tumours and systemic treatments but in the
case of superficial bladder cancer, the prospect of developing
predictive assays is more promising. As mentioned
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previously, MMC is used as a single agent to treat superficial
bladder cancer and this simplifies the assessment of clinical
response compared to other tumours where MMC is used in
combination with other cytotoxics. It is typically
administered intravesically within 24 hours of surgery and
this provides two key benefits. First, this route of drug
administration reduces pharmacokinetic variations in drug
exposure parameters compared to the wide inter-patient
variations typically observed following systemic or oral
administration. Second, the removal of the solid tumour
mass effectively removes any complications caused by
microenvironmental conditions. In addition, the comet assay
is relatively rapid and from a logistical point of view, it
should be feasible to obtain data within the 24 hour window
between surgery and chemotherapy. Future studies will
determine whether the comet assay or conceptually similar
approaches have predictive value in the clinic. 
With regards to the second issue, there are similarities
between MMC and current approaches used to develop
predictive assays for targeted therapies. The most obvious
of which is the use of single markers to identify those
patients whose tumours are most likely to respond. As
described above, the prospects of predicting tumour
response to MMC based upon analysis of a single enzyme
are poor, which raises the question of whether or not similar
mistakes are being made with the new generation of
targeted therapies? As in the case of enzyme directed
bioreductive drug development, the underlying principle is
that if a tumour expresses the target, then that tumour
should respond. If this is to be successful, the drug should
be specific for its target. Once the drug/target interaction
has occurred, downstream events leading to a therapeutic
response should be the same within a specific cancer type.
Whilst modern target orientated therapies are likely to have
a much simpler mechanism of action than MMC, it is
generally accepted that the majority of small molecule
therapeutics have multiple targets. In the case of Imatinib
for example, this compound was designed to inhibit tyrosine
kinase activity of the BCR-Abl protein produced by a single
genetic event in chronic myelogenous leukaemia.
Subsequent studies however demonstrated that imatinib is
also active against gastrointestinal stromal tumours that
harbour mutations in KIT (112). This illustrates the point
that even with targeted drugs, multiple targets and
mechanisms of action exist. 
Once the drug has bound or interacted with its target, will
this ultimately lead to a therapeutic response in all
circumstances? The tumour microenvironment is known to
influence therapeutic outcome and it is associated with
resistance to both radiotherapy and chemotherapy (113, 114).
Recent studies have demonstrated that oxygen deprivation
results in decreased expression of pro-apoptotic proteins
leading to decreased drug induced apoptosis and clonogenic
resistance in vitro (115). The tumour microenvironment may
therefore have a profound influence on therapeutic outcome,
independent of the expression of specific targets in tumour
cells. Within this theme, the three dimensional geometry of
solid tumours also introduces significant problems related to
drug delivery. The poor vascular supply, in conjunction with
high interstitial pressures within the tumour, is a recognised
barrier to the delivery of therapeutic agents (116, 117). Even
if tumour cells express the specific target, there can be no
guarantee that sufficient drug will be delivered to cells to
elicit a therapeutic response. Whilst significant challenges
exist, the use of assays that mimic more closely the
heterogeneity within tumours in terms of physiological
conditions and drug distribution represent a possible way
forward to achieving our goal of individualised therapy. 
In conclusion, whilst the modern era of targeted
therapeutics offers the potential to tailor therapy to
individual patients, past experience with chemotherapeutics
such as MMC has demonstrated that prediction of response
based on analysis of single target molecules is unlikely to be
accurate. Complex mechanisms of action and the effect of
the tumour microenvironment on cell biology and drug
delivery could thwart attempts to individualise therapies as
has been the case with many chemotherapeutic agents. The
challenge for the future is to develop assays that mimic key
aspects of tumour biology whist retaining the robustness,
simplicity and reliability required for routinely predicting
tumour response in a clinical setting. Furthermore,
incorporating such assays into pre-clinical and early clinical
studies would assist in the more rapid development and
evaluation of predictive assays. 
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